All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

2d agoen
Read on clinicaltrials.gov

From the article

Conditions : Local Advanced Rectal Cancer; PD-1 Inhibitor; PCSK9 Inhibitor; RCT; Radiotherapy; Capecitabine; Oxaliplatin Interventions : Radiation: Short-course radiotherapy; Drug: CAPOX (oxaliplatin/capecitabine); Drug: Sintilimab; Drug: Tafolecimab Sponsors : Guangdong Provincial People's Hospital; Beijing Friendship Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Fudan University; Sixth Affiliated Hospital, Sun Yat-sen University; Sun Yat-Sen University Cancer Center; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Affiliated Hospital of Qinghai University; Zhangzhou Hospital, Fujian Province; The First Affiliated Hospital of Xiamen University; Ruijin Hospital; The First Hospital of Jilin University; Peking University Cancer Hospital & Institute; Nanchang University Second Affiliated Hospital; The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine; Third Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Meizhou People's Hospital Not yet recruiting
Continue reading on clinicaltrials.gov

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.